Scholars Central

Conference abstractPublished 10 Mar 2025

The History of Ketamine and Its New Role in Treatment Resistant Depression

Authors: Roohi Abubaker

Morehouse School of Medicine, United States

Ask about this article

Abstract

Select any words in the title or abstract, or press this and choose a sentence.

Ketamine was first synthesized by an American Scientist in 1962, in 1963 patented in Belgium to be used in Veterinary anesthesia. This presentation will cover its changing roles in drug culture and used in Vietnam war and now recently growing interest in the use of both oral and I/V ketamine in treatment resistant depression. The advantages are fast action, wide therapeutic range and relatively lesser side effects. Will review recent study trials and will discuss its role in future treatment of depression. Treatment-Resistant Depression (TRD) is a serious, disabling illness, and has significant impact on social and occupational outcomes. Studies show 33% of patients do not achieve remission with conventional medications including those that target serotonin, norepinephrine, and dopamine. TRD patients may be started on adjunctive mood stabilizers, antipsychotics, as well as receive electro-convulsive therapy. Each of these modalities is not without unique side and sometimes irreversible side effects, and may require prolonged therapies for positive outcomes. Ketamine is an N-methyl-D-aspartate receptor antagonist, which has been shown to result in anti-depressant effects within 24 hours. Ketamine has a short half-life of 2-3 hours, and may be given intravenous, subcutaneous, intranasal, or oral formulation. This poster will discuss several studies that indicate ketamine’s role as an antidepressant. Ketamine metabolite (2R, 6R)-hydroxynorketamine (HNK) is essential for antidepressant effects in mice. It exerts its effects that are NMDAR-independent. HNK blocks synaptic NMDAR's in a similar manner, which subsequently elicits signaling of the transduction pathways, increases brain derived neurotrophic factor expression, and increases synaptic potentiation in the hippocampus. This mechanism supports why short halflife ketamine can have a long lasting anti-depressive effect.

Ask about this article

Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.

Try:

More from this journal

The newest in Journal of Psychology & Psychotherapy.

All its articles

Conferences in this field

Upcoming conferences in this field.

Follow

New articles from what you follow go into your email digest, once you agree to alert emails.

  • JournalJournal of Psychology & Psychotherapy
  • SubjectMental Health and Psychology
  • BylineArticles whose byline prints “Roohi Abubaker”